Fractyl Health (GUTS) Stock Price, News & Analysis

Company Overview

Fractyl Health, Inc. is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine. This outpatient procedure is designed to interrupt disease-driving signals between the gut and the liver, pancreas and brain, with the aim of improving glycemic control and reducing liver fat. Fractyl has conducted multiple clinical trials across North America, Europe and Asia, and holds CE mark approval in the European Union for Revita DMR.

Fractyl Health is also developing next-generation therapies and combination approaches to expand the reach of its duodenal resurfacing technology. The company has initiated pivotal studies to support U.S. regulatory filings and is preparing for broader commercial roll-out following anticipated approvals. Fractyl’s management team includes industry veterans in interventional gastroenterology, clinical development and medical device commercialization, positioning the company to address the growing global burden of metabolic disease.

Key Stats

• Today's Range: $0.76 to $0.81
• 50-Day Range: $0.58 to $0.95
• 52-Week Range: $0.38 to $2.45
• Volume: 841,299 shs
• Average Volume: 3.72 million shs
• Market Capitalization: $120.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.12
• Consensus Rating: Moderate Buy

Fractyl Health Stock Analysis - MarketRank™

Fractyl Health scored higher than 91% of companies evaluated by MarketBeat, and ranked 42nd out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Fractyl Health has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Fractyl Health has a consensus price target of $5.12, representing about 571.9% upside from its current price of $0.76.

Amount of Analyst Coverage

Fractyl Health has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Fractyl Health are expected to grow in the coming year, from ($0.60) to ($0.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fractyl Health is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fractyl Health is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Fractyl Health has a P/B Ratio of 10.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.60% of the float of Fractyl Health has been sold short.

Short Interest Ratio / Days to Cover

Fractyl Health has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fractyl Health has recently decreased by 3.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fractyl Health does not currently pay a dividend.

Dividend Growth

Fractyl Health does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

Fractyl Health has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Fractyl Health this week, compared to 4 articles on an average week.

Search Interest

13 people have searched for GUTS on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.

MarketBeat Follows

4 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

5 insiders have purchased shares of Fractyl Health in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $127,150.00 in company stock, which represents 0.1052% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Fractyl Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $127,150.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

8.52% of the stock of Fractyl Health is held by insiders.

Percentage Held by Institutions

Fractyl Health has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 7/02/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:GUTS
• Previous Symbol: NASDAQ:GUTS
• CIK: 1572616
• Web: fractyl.com
• Phone: 781-902-8800
• Fax: N/A
• Employees: 102
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Fractyl Health: $5.12
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +571.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -4,053.15%
• Return on Assets: -96.41%

Debt

• Debt-to-Equity Ratio: 1.41
• Current Ratio: 4.28
• Quick Ratio: 4.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 10.89

Miscellaneous

• Outstanding Shares: 158,649,000
• Free Float: 145,132,000
• Market Cap: $120.89 million
• Optionable: N/A
• Beta: 2.29